Prognostic evaluation of immunohistochemical profiles in diffuse large B-cell lymphoma: A Chinese study

Medical Oncology

Volumn 28, Issue 1, 2011, Pages 241-248

  Chen, Zi ^a   Du, Zunguo ^a   Chen, Jieqing ^b   Chen, Zhongqing ^a   Bao, Yun ^a   Tang, Feng ^a  

^a FUDAN UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Diffuse large B cell lymphoma; Immunohistochemical profile; Survival analysis

Indexed keywords

CD5 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; INTERFERON REGULATORY FACTOR 4; PREDNISOLONE; PROTEIN BCL 6; RITUXIMAB; SYNDECAN 1; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ALGORITHM; ANTIGEN EXPRESSION; ARTICLE; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CHINESE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; HANS ALGORITHM; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MURIS ALGORITHM; OVERALL SURVIVAL; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; STEM CELL TRANSPLANTATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD5; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHINA; COMBINED MODALITY THERAPY; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; INTERFERON REGULATORY FACTORS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEPRILYSIN; PROGNOSIS; RADIOTHERAPY DOSAGE; SURVIVAL RATE; SYNDECAN-1; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 79952244267     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-010-9433-3     Document Type: Article

References (27)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997;89:3909-18.
2. Jafe ES, et al. World Health Organization Classification of tumors pathology and genetics: tumors of haematopoietic and lymphoid tissues [M]. Lyon: lARC Press; 2001. p. 171-4.
3. IS Lossos 2005 Molecular pathogenesis of diffuse large B-cell lymphoma J Clin Oncol 23 6351 6357 16155019 10.1200/JCO.2005.05.012 1:CAS:528: DC%2BD2MXhtFWntbbO (Pubitemid 46218846)
4. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: a predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329:987-94.
5. AA Alizadeh, et al. 2000 Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling Nature 403 503 511 10676951 10.1038/35000501 1:CAS:528:DC%2BD3cXht1Shtrg%3D (Pubitemid 30082188)
6. A Rosenwald, et al. 2002 Lymphoma/Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma N Engl J Med 346 1937 1947 12075054 10.1056/NEJMoa012914 (Pubitemid 34651353)
7. CP Hans, et al. 2004 Confirmation of the molecular classification of diffuse large B cell lymphoma by immunohistochemistry using a tissue microarray Blood 103 275 282 14504078 10.1182/blood-2003-05-1545 1:CAS:528: DC%2BD2cXhsFGhsA%3D%3D (Pubitemid 38029949)
8. CC Chang, et al. 2004 Immunohistochemical expression patterns of germinal center and activation B cell markers correlate with prognosis in diffuse large B cell lymphoma Am J Surg Pathol 28 464 470 15087665 10.1097/00000478-200404000- 00005 (Pubitemid 38436519)
9. JJF Muris, et al. 2006 Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma J Pathol 208 714 723 16400625 10.1002/path.1924 1:CAS:528:DC%2BD28XjvV2nsbg%3D
10. S Harada, et al. 1999 Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5- with CD10 + groups may constitute clinically relevant subtypes Leukemia 13 1441 1447 10482997 10.1038/sj.leu. 2401487 1:CAS:528:DyaK1MXmsFGktrc%3D (Pubitemid 29429773)
11. L Colomo, et al. 2003 Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma Blood 101 78 84 12393466 10.1182/blood-2002-04-1286 1:CAS:528: DC%2BD3sXhtFSqtw%3D%3D (Pubitemid 36025890)
12. MB Moller, et al. 2006 Conditional survival of patients with diffuse large B-cell lymphoma Cancer 106 2165 2170 16586498 10.1002/cncr.21877 (Pubitemid 43673238)
13. A López-Guillermo, et al. 2005 Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin J Clin Oncol 23 2797 2804 15728226 10.1200/JCO.2005.07.155 (Pubitemid 46179470)
14. RB Wilder, et al. 2002 International prognostic index-based outcomes for diffuse large B-cell lymphomas Cancer 94 3083 3088 12115338 10.1002/cncr.10583 (Pubitemid 34670490)
15. B Coiffier, et al. 2002 CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med 346 235 242 11807147 10.1056/NEJMoa011795 1:CAS:528:DC%2BD38XmslGgsw%3D%3D (Pubitemid 34438862)
16. A Dogan, et al. 2000 CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas Am J Surg Pathol 24 846 852 10843287 10.1097/00000478-200006000-00010 1:STN:280:DC%2BD3czgtVaksQ%3D%3D (Pubitemid 30366272)
17. L de Leval NL Harris 2003 Variability in immunophenotype in diffuse large B-cell lymphoma and its clinical relevance Histopathology 43 509 528 14636252 10.1111/j.1365-2559.2003.01758.x (Pubitemid 38002340)
18. G Wu A Keating 2006 Biomarkers of potential prognostic significance in diffuse large B-cell lymphoma Cancer 106 247 257 16342164 10.1002/cncr.21586 1:CAS:528:DC%2BD28XjslOmtbc%3D (Pubitemid 43100431)
19. S Montes-Moreno, et al. 2008 Gcet1 (centerin), a highly restricted marker for a subset of germinal center-derived lymphomas Blood 111 351 358 17898315 10.1182/blood-2007-06-094151 1:CAS:528:DC%2BD1cXjtVKnuw%3D%3D
20. M Berglund, et al. 2005 Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis Mod Pathol 18 1113 1120 15920553 10.1038/modpathol.3800396 1:CAS:528:DC%2BD2MXmtlCrsrw%3D (Pubitemid 41224503)
21. M Yamaguchi, et al. 2002 De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients Blood 99 815 821 11806981 10.1182/blood.V99.3.815 1:CAS:528:DC%2BD38XhtValsL0%3D (Pubitemid 34525540)
22. T Katzenberger, et al. 2003 Genetic analysis of de novo CD5+ diffuse large B-cell lymphomas suggests an origin from a somatically mutated CD5+ progenitor B cell Blood 101 699 702 12393524 10.1182/blood-2002-06-1726 1:CAS:528:DC%2BD3sXkvVajsA%3D%3D (Pubitemid 36077595)
23. YH Oh CK Park 2006 Prognostic evaluation of nodal diffuse large B cell lymphoma by immunohistochemical profiles with emphasis on CD138 expression as a poor prognostic factor J Korean Med Sci 21 397 405 16778379 10.3346/jkms.2006. 21.3.397 1:CAS:528:DC%2BD28XnslSjt7s%3D
24. F Amen, et al. 2007 Absence of cyclin-D2 and Bcl-2 expression within the germinal centre type of diffuse large B-cell lymphoma identifies a very good prognostic subgroup of patients Histopathology 51 70 79 17593082 10.1111/j.1365-2559.2007.02721.x 1:STN:280:DC%2BD2szns1KmtQ%3D%3D (Pubitemid 46976368)
25. J Jabłońska D Jesionek-Kupnicka 2008 Usefulness of immunohistochemistry in identification of prognostically important subgroups (GCB and ABC) in a heterogeneous group of diffuse large B-cell lymphomas-a review article Pol J Pathol 59 121 127 19097355
26. Tzankov A, et al. Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores. Leuk Lymphoma. 2009; [Epub ahead of print].
27. D de Jong, et al. 2009 Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue micro-array as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium) J Clin Pathol 62 128 138 18794197 10.1136/jcp.2008.057257